COMMUNIQUÉS West-GlobeNewswire

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
22/09/2025
Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage [...]
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics
22/09/2025
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics Helio Diagnostics is backed by a team with 25+ years of experience in the development and manufacturing of complex diagnostic devices. Marseille, [...]
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22/09/2025
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma [...]
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
22/09/2025
ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled [...]
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
22/09/2025
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial ZUG, Switzerland, Sept. 22, 2025 ( [...]
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
22/09/2025
MILAN, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised [...]
C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme
22/09/2025
C4X Discovery Holdings Ltd C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to support once-daily [...]
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
22/09/2025
Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role [...]
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
22/09/2025
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30 th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics [...]
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre
22/09/2025
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre NANTES, France – 22 septembre 2025, 8 h 00 – OSE [...]
CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE®
22/09/2025
Communiqué de presse CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE® DIJON, France – 22 septembre 2025 (07H30 CET) – CROSSJECT (ISIN [...]
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
22/09/2025
Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT (ISIN: [...]
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22/09/2025
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1 -mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The [...]
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
22/09/2025
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin [...]
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l’étude de Phase III
22/09/2025
L'IPN10200 est une molécule recombinante, première de sa classe (« first-in-class »), spécifiquement conçue pour obtenir une affinité et une internalisation accrues du récepteur, offrant ainsi une durée d’action [...]
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22/09/2025
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration (FDA) has extended by three months the target [...]
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
22/09/2025
IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacy Data showed [...]
Communiqué de presse : Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente
22/09/2025
Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Paris, le 22 septembre 2025 . La Food and Drug Administration (FDA [...]

Pages